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Identity 
Other names: API1; C-IAP1; HIAP-2; HIAP2; Hiap-
2; IAP2; MIHB; RNF48; cIAP1; hiap-2 





31,436 bp, 9 exons. 
Transcription 




618 amino acids. The protein contains three motifs, i.e., 
BIR (Baculoviral Inhibitor of Apoptosis Repeat) 
domain, RING (Really Interesting New Gene)-finger 
domain, and CARD (Caspase Recruitment Domain). 
Expression 
Wide, highly expressed in large intestine, lung, 
endometrium, bladder and salivary gland. 
Localisation 
Cytoplasmic and/or nucleus. 
Function 
Inhibition of apoptosis by preventing the proteolytic 
processing of procaspase-3, procaspase-6, and 
procaspase-7, by inhibiting the cytochrome C-induced 
activation of procaspase-9; by binding to tumor 
necrosis factor receptor-associated factor II (TRAF2) 
and enhancing TRAF2-induced NF-kappaB activity 
that protects TRAF2 from ubiquitination in cells; by 
promoting the proteasome-dependent degradation of 
Smac/DIABLO through E3 ubiquitin ligase activity of 
their RING finger domains; and by direct 
ubiquitination of RIP1 in cancer cells and its 
association with the prosurvival kinase TAK1 (TGF-









All cIAP1/BIRC2, cIAP2 and XIAP were expressed in 
most of 240 non-Hodgkin lymphoma and all 40 
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In non-Hodgkin lymphomas, cIAP1 was expressed in 
73%, cIAP2 in 48% and XIAP in 15%. cIAP was 
positive in all precursor B-cell lymphoblastic 
lymphoma/leukemia and nodal marginal zone B-cell 
lymphoma, over 90% of follicular lymphoma and 
diffuse large B-cell lymphoma, and approximately 50 
to 60% of myeloma, Burkitt lymphoma, 
lymphoplasmacytic lymphoma, small lymphocytic 
lymphoma/chronic lymphocytic leukemia, extranodal 
marginal zone B-cell lymphoma of mucosa associated 
lymphoid tissue (MALT-lymphoma), splenic marginal 
zone lymphoma, and mantle cell lymphoma.  
In Hodgkin lymphomas, cIAP was positive in 75%, and 
were not correlated with histologic type (Akyurek et 
al., 2006). Treatment of diffuse large B-cell lymphoma 
cells with bortezomib caused apoptosis via involving 
the mitochondrial pathway and activation of caspases, 
and finally down-regulate the expression of cIAP1, 
XIAP and survivin (Uddin et al., 2008). Among 
multiple myeloma patients with increased multidrug-
resistant (MDR) 1 expression after chemotherapy, 
those with a poor outcome exhibited significant 
increase in survivin, cIAP1, cIAP2, and XIAP 
expression by chemotherapy compared with those with 
a good prognosis. Similarly, in the lung resistance 
protein (LRP) expression-increased group, patients 
with a poor outcome showed significant increase of 
cIAP1 and cIAP2 expression compared with those with 
longer survival (Nakagawa et al., 2006). An integrated 
analysis of high-density oligonucleotide array CGH and 
gene expression profiling data from 155 multiple 
myeloma samples identified a promiscuous array of 
abnormalities contributing to the dysregulation of NF-
KB in approximately 20% of patients. Mutations in 10 
genes causing the inactivation of TRAF2, TRAF3, 
CYLD, cIAP1/cIAP2 and the activation of NF-
kappaB1, NF-kappaB2, CD40, LTBR, TACI, and NIK 
that result primarily in constitutive activation of the 
noncanonical NF-KB pathway, with the single most 
common abnormality being inactivation of TRAF3 
(Keats et al., 2007). 
Myelodysplastic syndrome 
Note 
Overexpression of mRNA for survivin, cIAP1, NAIP 
and XIAP was significant in myelodysplastic syndrome 
bone marrow cells compared with control samples. 
However, the expression of mRNA for survivin, cIAP1 
and cIAP2 exhibited a remarkable decrease after the 
development of overt leukemia (Yamamoto et al., 
2004). 
Squamous cell carcinoma of head and 
neck (HNSCC) 
Note 
Nuclear cIAP-1 expression was positive in 30% of 
HNSCC, was correlated with lymph node metastasis 
and advanced disease stage, and tends to be correlated 
with poor patient prognosis. Nuclear cIAP-1 expression 
was inversely correlated with caspase-3 expression, but 
was correlated with Smac/DIABLO expression. 
Nuclear cIAP-1 expression appears to be a useful 
marker for predicting poor patient prognosis in 
HNSCCs, and may play roles in HNSCC through the 
signaling pathway mediated by Smac/DIABLO and 
caspase-3 (Tanimoto et al., 2005). Nuclear, cytoplasmic 
and concurrent cIAP-1 immunoreactions were 
significantly correlated with lymph node metastasis in 
tongue SCCs. Concurrent cIAP-1 expression was 
inversely correlated with caspase-3, but was positively 
correlated with Ki-67 expression. Both nuclear and 
cytoplasmic patterns of cIAP-1 expression were useful 
markers for predicting cervical lymph node metastasis 
in tongue SCC (Qi et al., 2008). 
Squamous cell carcinoma (SCC) of 
esophagus 
Note 
High copy-number amplification at 11q21-q23 was 
identified in cell lines derived from esophageal SCCs 
using comparative genomic hybridization. Only cIAP1 
was consistently overexpressed in cell lines that 
showed amplification. cIAP1 protein was 
overexpressed in the primary tumors from which those 
cell lines had been established. cIAP1 is likely to be a 
target for 11q21-23 amplification and may be involved 
in the progression of esophageal SCC (Imoto et al., 
2001). 
Squamous cell carcinoma (SCC) of 
uterine cervix 
Note 
In the 2 of 9 cell lines of cervical SCC showed 
amplification and consistent overexpression of cIAP1, 
as well as significant resistance to radiation-induced 
cell death as compared with cell lines showing no 
cIAP1 amplification. Both overall survival and local 
recurrence-free survival rates were significantly lower 
among patients with tumors showing high levels of 
nuclear cIAP1 staining than among patients whose 
tumors revealed little or no nuclear cIAP1. Multivariate 
analyses showed nuclear cIAP1 staining to be an 
independent predictive factor for local recurrence-free 
survival after radiotherapy among patients with cervical 
SCC (Imoto et al., 2002). 
Adenoid cystic carcinoma of lacrymal 
gland 
Note 
Expression of cIAP1, cIAP2, XIAP and survivin was 
higher in adenoid cystic carcinoma than in pleomorphic 
adenoma of the lacrymal gland (Liao et al., 2009). 
Nasopharyngeal carcinoma (NPC) 
Note 
Among the IAPs family, only trancription of survivin, 
HIAP-1 and HIAP-2/BIRC2 was consistently up-
regulated in nasopharyngeal carcinoma (NPC) and 
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metastatic NPC tissues. Immunohistochemical staining 
showed that their proteins were more predominantly 
expressed in tumor cells nests. Survivin, HIAP-1 and 
HIAP-2 were upregulated by interleukin-1 alpha 
stimulation or EBV infection, and subsequently 
resulted in triggering rapid proliferation of NPC (Chua 
et al., 2008). 
Lung cancer 
Note 
Amplification of chromosome 11q22 was detected in 
primary tumors and lung cancer cell lines of both non-
small cell lung cancer and small cell lung cancer. Gene 
localized in this region included cIAP1 and cIAP2. 
Immunohistochemistry and western blot analysis 
identified cIAP1 and cIAP2 as potential oncogenes in 
this region as both were overexpressed in multiple lung 
cancers (Dai et al., 2003). 
Malignant pleural mesothelioma 
Note 
IAP-1 was overexpressed in malignant pleural 
mesothelioma and is responsible for a large degree of 
the resistance of cultured mesothelioma cells to 
cisplatin. Levels of circulating TNF-alpha were 
significantly higher in mesothelioma patients prior to 
surgical tumor debulking compared with those after 
surgery. TNF-alpha could increase mRNA and protein 
levels of IAP-1, IAP-2 and XIAP. IAP gene expression 
levels were increased concomitantly with translocation 
to the nucleus of the TNF-responsive transcription 
factor NF-KB (Gordon et al., 2007). 
Renal cell carcinoma 
Note 
Overexpression of cIAP1 and cIAP2 occurred in most 
renal cell carcinoma specimens, but 20% of the patients 
had lower cIAP levels in malignant than in normal 
tissue. The cIAP1 expression correlated with the tumor 
stage, levels being higher in pT1 tumors than in 
advanced pathological stages. Decreased cIAP1 
expression in renal cell carcinoma relative to paired 
normal samples predicted an abbreviated time to 
recurrence and tumor-specific survival irrespectively of 
the tumor stage and grade. The prognostic effect of 
cIAP1 was most pronounced in patients with pT3 
disease. The results of uni- and multivariate analyses 
suggested a prognostic value of cIAP1 expression for 
renal cell carcinoma patients, downregulation 
indicating an aggressive, potentially lethal phenotype 
(Kempkensteffen et al., 2007). 
Pancreatic neoplasms 
Note 
cIAP1 expression was constantly high in non-
neoplastic pancreatic tissues, in pancreatic 
intraepithelial neoplasia lesions, as well as in a subset 
of primary and metastatic pancreatic ductal 
adenocarcinomas, and a preferential cytoplasmic 
localisation was observed in the tumor tissues. cIAP 
expression was rare in a cystic tumors. Survival 
analyses revealed a shorter survival in patients with 
cIAP1/cIAP2-positive tumors (Esposito et al., 2007). 
Endometrial cancer 
Note 
cIAP-1 expression was high in endometrial cancer cells 
expressing phospho-Akt. Akt phosphorylation 
decreased and apoptosis was strongly increased in 
PTEN-mutated endometrial cancer cells in the presence 
of phosphatidylinositol 3 kinase (PI3-K) inhibitor 
which was accompanied by a down-regulation of cIAP-
1. Overexpression of Akt using a constitutively active 
Akt expression vector resulted in an up-regulation of 
cIAP-1 expression. Akt regulated endometrial cancer 
cell survival through the up-regulation of cIAP-1 
(Gagnon et al., 2003). 
Various cancer cell lines 
Note 
cIAP1 and XIAP were expressed in most cancer lines 
analised, with substantial variability in their relative 
levels. Higher levels of cIAP1 protein were associated 
with resistance to several anticancer drugs (Tamm et 
al., 2000). IAPs were induced by NF-KB or v-Rel in 
multiple cell lines and conversely, HIAP1 and HIAP2 
activated NF-kappaB possibly forming a positive feed-
back loop (LaCasse et al., 1998). cIAP1 and cIAP2 
promoted cancer cell survival by functioning as E3 
ubiquitin ligases that maintain constitutive 
ubiquitination of the RIP1 adaptor protein (Bertrand et 
al., 2008). 
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